Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06881894 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-06881894 | EXPERIMENTAL | PF-06881894 6 mg SC |
| US-approved Neulasta | ACTIVE_COMPARATOR | US-approved Neulasta 6 mg SC |
| Name | Type | Description |
|---|---|---|
| PF-06881894 | BIOLOGICAL | pre-filled syringe 6 mg |
| US-approved Neulasta | BIOLOGICAL | pre-filled syringe 6 mg |
Inclusion Criteria: • Healthy males or females between 18 and 65 years of age (both inclusive) with body mass index between 19 and 30 kg/m2, inclusive, and body weight of not \<50 kg or \>95 kg, will be enrolled in this study. Exclusion Criteria: * Hematologic laboratory abnormalities (including ...
PF-06881894 is a monoclonal antibody being studied in healthy volunteers. It is currently in Phase 1 clinical development and is not approved for any indication. The drug is being investigated for its immune response effects in healthy individuals.
PF-06881894 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange. The company is conducting clinical trials to evaluate the drug's safety and immune response in healthy volunteers.
PF-06881894 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its immune response and safety profile.
PF-06881894 has one completed Phase 1 clinical trial, NCT03273842, which assessed immune response to multiple doses of the drug compared to US-approved Neulasta in healthy volunteers. The trial enrolled 422 participants in the United States.
PF-06881894 is not the same as Neulasta, but it is being compared to US-approved Neulasta in a clinical trial. The study NCT03273842 evaluated immune response to multiple doses of PF-06881894 or Neulasta in healthy volunteers.